The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, to double its size and capacity.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna (ataluren), PTC Therapeutics’ treatment for the genetic disease Duchenne muscular dystrophy (DMD).
The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major depressive disorder and generalized anxiety disorder.
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the evolving landscape.
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.
At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to immerse themselves in its patient-inspired innovations.
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
As local and state governments in the US begin to receive and distribute their opioid settlement funds, Sonara Health has developed a comprehensive report analyzing how over $50 billion in national funds can be effectively allocated to address the opioid...
Dalgety, one of the UK's leading medical cannabis cultivators, has achieved a significant milestone by securing a Home Office licence to supply medical cannabis within the UK.
H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most.
Ayvakit, a groundbreaking therapy developed by Blueprint Medicines, has witnessed a remarkable 185% year-over-year revenue growth in the second quarter of this year (2024).
Lonza, a global leader in the pharmaceutical, biotech, and nutraceutical markets, has announced a significant expansion of its clinical manufacturing services at its small molecules site in Bend, Oregon.
As the BioSecure Act approaches its 2032 implementation, Contract Development and Manufacturing Organizations (CDMOs) must prepare for significant industry shifts.
Rusan Pharma Private Limited has announced that its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat, has been granted Good Manufacturing Practice (GMP) approval by the FDA.
Psychedelic therapeutics have rapidly gained popularity in the pharma industry in a matter of just a few years. Here are five psychedelic drug discovery startups that have received investment this year.
Today (July 16) Celadon Pharmaceuticals Plc, a trailblazer in the UK’s pharmaceutical industry, has achieved a significant milestone with the successful completion of its eighth cannabis harvest of 2024.
Cellibre, a leader in sustainable biochemical manufacturing, has secured a $2 million grant from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH).
Ketaki Patwardhan, a global technical developer at Roquette, has built a remarkable career in the pharmaceutical industry by leveraging her curiosity and passion for science.
In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.
dsm-firmenich has announced the launch of CBtru – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.
Preclinical results show promise for Tyra Bioscience’s lead drug candidate for the treatment for hypochondroplasia, a condition for which there are currently no therapeutic options available.
The Spanish company Esteve Pharmaceuticals is building a manufacturing unit in its Girona plant with the aim to expand its production of active pharmaceutical ingredients (APIs).
Cellibre, a pioneer in sustainable biochemical manufacturing, has received a $2 million grant from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH).
Hikma Pharmaceuticals PLC has made a significant announcement, marking the US launch of Combogesic IV, an intravenous, opioid-free pain relief medication providing a multimodal approach to managing pain in adults.
In an inspiring conversation with Liza Laws, Dr. Michael Giles, MD, and chief executive officer of Sonara Health, shares the innovative journey of creating a platform to enhance the accessibility of methadone treatment for opioid use disorder patients.
In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.
UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.
Today (May 14) Everest Medicines, a biopharmaceutical company focused on progressive medicines and vaccines, announced the successful launch of small molecule Nefecon, a delayed-release capsule, in China, with the first prescription issued.
Roquette, a global leader in plant-based ingredients and a key provider of pharmaceutical and nutraceutical excipients, announced today (May 14) the launch of its innovative Lycagel Flex hydroxypropyl pea starch premix for softgel capsules.
Sanofi, a global pharmaceutical giant, has announced a significant investment of over €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
In an extensive and enlightening chat with Prasad Raje, the CEO of LGM Pharma, OSP gained profound insights into the company's trajectory within the pharmaceutical industry.
After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.
In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
